Answers are grounded in this paper and cite their sources.
An open label Phase-1 proof-of-concept study evaluated the safety and immunogenicity of IMNN-101, a DNA vaccine based on an expression plasmid and a synthetic delivery carrier (the PlaCCine vaccine), in healthy human adults previously vaccinated or infected with SARS-CoV-2. Study participants received a single intramuscular dose of 0.5 mg, 1.0 mg, or 2.0 mg of IMNN-101 DNA vaccine (n = 8 participants per group). Mild to moderate reactogenicity events were observed in 67% (16/24) of participants, including tenderness, hardening, pain, redness, swelling, and itching at the injection site, as well as fatigue, muscle aches, headache, and nausea/vomiting. Fourteen grade 1 or 2 treatment-emergent adverse events were reported: none of those attributed to IMNN-101. There were no reports of myocarditis or pericarditis. The immunization with IMNN-101 resulted in an increase in neutralizing antibody (NAb) titers against XBB.1.5 and other circulating variants of SARS-CoV-2, with 2-3-fold increase in NAb titers that were maintained during the 6-month follow up. This first-in-human evaluation of a PlaCCine-based DNA vaccine demonstrates a favorable safety profile and durable humoral immune response. The PlaCCine vaccine is thermostable, does not require a device or virus for delivery, and offers a viable alternative approach to immunization.
No takes yet. Share an insight, caveat, or question.
Anwer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: